The Effect of Carriage of CYP3A5*3 and CYP3A4*22 Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19

The aim of the study was to assess the association of polymorphic variants CYP3A5*3 6986 A>G rs776746 and CYP3A4*22 rs35599367 C>T with the safety parameters of remdesivir therapy in patients with COVID-19.
Material and methods. The study included 156 patients admitted to the City Clinical Hospital No. 15 of the Moscow Health Department with COVID-19 diagnosis, who received remdesivir as an antiviral drug. The frequency of adverse reactions (bradycardia, dyspeptic disorders), as well as various laboratory parameters (ALT, AST, creatinine, ferritin, interleukin-6, and d-dimer levels) were compared between the carriers of wild-type and polymorphic variants of the studied genes.
Results. Carriers of CYP3A5*3 polymorphic variants (GA+AA) had higher ALT levels after the treatment with remdesivir than carriers of the wild variant (GG). When comparing the level of interleukin-6 after therapy with remdesivir, carriers of the polymorphic variant of the CYP3A4*22 (CT) gene had a significantly higher level of this cytokine.
Conclusion. An association between the carriage of polymorphic variants of CYP3A5*3 and an increase in the level of liver enzymes was found. Polymorphic variants of CYP3A4*22 were associated with higher levels of interleukin-6. Additional pharmacogenetic studies are required to assess the possibilities of personalizing antiviral therapy for COVID-19.

1. Agostini M.L., Andres E.L., Sims A.C. et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio. 2018; 9 (2): e00221–18. doi:10.1128/mBio.00221-18.

2. Wang M., Cao R., Zhang L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30 (3): 269–271. doi:10.1038/s41422-020-0282-0

3. Beigel J.H., Tomashek K.M., Dodd L.E. et al. Remdesivir for the Treatment of COVID-19 — Final Report. N Engl J Med. 2020; 383 (19): 1813–1826. doi:10.1056/NEJMoa2007764.

4. Goldman J.D., Lye D.C.B., Hui D.S. et al. Remdesivir for 5 or 10 Days in Patients with Severe COVID-19. N Engl J Med. 2020; 383 (19): 1827–1837. doi:10.1056/nejmoa2015301.

5. Safety of Remdesivir and Tocilizumab in COVID-19 Treatment. Safety and Risk of Pharmacotherapy. 2020; 8 (3): 160–162. https://doi.org/10.30895/2312-7821-2020-8-3-160-162. (in Russian)

6. European Medicnes Agency Summary on Compassionate Use of Remdesivir. [(accessed on 15 March 2021)]; Available online: https://www.ema.europa.eu/en/documents/other/summary-compassionate-useremdesivir-gilead_en.pdf

7. Deb S., Reeves A.A. Simulation of remdesivir disposition and its drug interactions. J Pharm Pharm Sci. 2021; 24: 277–291. doi:10.18433/jpps32011.

8. Werk A.N., Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol Ther. 2014; 96 (3): 340–348. doi:10.1038/clpt.2014.129.

9. Birdwell K.A., Decker B., Barbarino J.M. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015; 98 (1): 19–24. doi:10.1002/cpt.113.

10. Moes D.J.A.R., Swen J.J., Den Hartigh J. et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation. CPT Pharmacometrics Syst Pharmacol. 2014; 3 (2): e100. doi:10.1038/psp.2013.78.

11. Lunde I., Bremer S., Midtvedt K. et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol. 2014; 70 (6): 685–693. doi:10.1007/s00228-014-1656-3.

12. Kitzmiller J.P, Sullivan D.M, Phelps M.A., Wang D., Sadee W. CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. Drug Metabol Drug Interact. 2013; 28 (1): 59–63. doi:10.1515/dmdi-2012-0031.

13. Elens L., Becker M.L., Haufroid V. et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics. 2011; 21 (12): 861–866. doi:10.1097/FPC.0b013e32834c6edb.

14. Moon A.M., Barritt A.S. Elevated Liver Enzymes in Patients with COVID-19: Look, but Not Too Hard. Dig Dis Sci. 2021; 66 (6): 1767–1769. doi:10.1007/s10620-020-06585-9.

15. Kalligeros M., Shehadeh F., Mylona E., Wands J.R., Mylonakis E. Poster Abstracts. Hepatology. 2021; 74 (S1):157–1288. doi:10.1002/hep.32188.

16. Majidpoor J., Mortezaee K. Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. Biomed Pharmacother. 2022; 145: 112419. doi:10.1016/J.BIOPHA.2021.112419.